A Drug Safety Evaluation of Dapagliflozin for Diabetic Nephropathies in Patients with Cardiovascular Risk

Diabetic nephropathy isa significant concern for patients with cardiovascular disease. Dapagliflozin,an SGLT2 inhibitor, has emerged as a promising therapeutic approach to managingdiabetic nephropathy and reducing cardiovascular risk. This reviewencompasses the research and literature search methodology, including clinicaltrials and real-world evidence, assessing the safety profile of Dapagliflozinin patients with diabetic nephropathy and cardiovascular risk. Dapagliflozin, an SGLT2 inhibitor, hasredefined patient-centric care by simultaneously improving glycemic control,cardiovascular health, and renal outcomes in individuals with type 2 diabetes,cardiovascular disease, and nephropathy.